Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2019
Event: Entry into a Material Definitive Agreement (Indenture) and termination of a prior Credit Agreement.
Key Financial Metrics and Transaction Details
- Debt Issuance: Issued $70.0 million aggregate principal amount of 12.5% senior secured notes due 2025.
- Equity Component: Issued warrants to purchase up to 2,000,000 shares of common stock at an initial exercise price of $4.25.
- Net Proceeds: Estimated at approximately $67 million after deducting offering expenses.
- Debt Repayment: Used proceeds to repay approximately $52 million in outstanding obligations under the previous Credit Agreement (principal, accrued interest, and fees).
- Interest Rate: 12.5% per annum, payable quarterly commencing September 30, 2019.
- Maturity: June 30, 2025.
- Collateral: Notes are secured by a first priority lien on substantially all company assets and a pledge of subsidiary equity interests.
Material Changes Versus Prior Period
The filing represents a significant restructuring of the company's capital structure:
- Termination of Prior Debt: The previous Credit Agreement dated August 16, 2016, was fully terminated and paid off.
- New Debt Structure: Replaced the prior facility with senior secured notes carrying a higher fixed interest rate (12.5%) and a longer maturity (2025).
- Amortization: The new notes include a fixed amortization schedule for principal payments commencing September 30, 2021.
- Equity Dilution: Introduction of 2,000,000 warrants exercisable until June 30, 2025.
Guidance, Outlook, and Material Provisions
Use of Proceeds: Net proceeds were used to repay the prior Credit Agreement and for general corporate purposes.
Additional Issuance Options: The Indenture allows for the issuance of up to an additional $30.0 million in notes (total potential issuance of $100.0 million) contingent on specific milestones:
- First Additional Notes ($10.0 million): Available if a new drug application (NDA) for Libervant is filed with the FDA by March 31, 2021, subject to holder consent.
- Second Additional Notes (up to $30.0 million): Available if Libervant receives FDA approval by March 31, 2021.
Apomorphine Disposition Provisions:
- Upon an "Apomorphine Disposition" (sale of rights or fixed cash payments related to Apomorphine), the Company must offer to repurchase Notes at 112.5% of principal plus accrued interest.
- Cash proceeds from such dispositions (up to agreed amounts) must be deposited into a segregated Collateral Account until Libervant FDA Approval is received.
Change of Control: Holders may require repurchase at 101% of principal plus accrued interest upon a Change of Control.
Asset-Based Lending (ABL): The Company may enter into an ABL facility up to $10 million if it achieves at least $75 million in net revenues for the most recently completed twelve-month period.
Investor Verification Checklist
- Verify the exact net proceeds received versus the estimated $67 million.
- Confirm the status of the Libervant NDA filing and FDA approval timeline relative to the March 31, 2021 deadline for additional note issuance.
- Review the specific terms of the "Apomorphine Disposition" to understand potential cash flow restrictions and mandatory repurchase obligations.
- Assess the impact of the 12.5% interest rate and quarterly amortization (starting 2021) on future liquidity and cash flow.
- Monitor the company's ability to meet the $75 million revenue threshold required to access the optional $10 million ABL facility.